 Product Service News
May 30, 2024
Red Violet Inc. Outshines Competitors Amidst Strategic Partnerships and Revenue Growth In an era defined by data-driven decisions and technological advancements, companies that are able to leverage strategic partnerships and revenue growth often find themselves on a path to success. This has certainly been the case ...
|
Clinical Study
May 30, 2024
In a groundbreaking discovery, researchers have utilized the innovative Olink Explore platform to identify specific proteins circulating in the blood that may serve as early warning signs for various types of cancers up to 7 years before conventional diagnosis methods. This landmark study sheds new light on the pote...
|
Announcement
May 30, 2024
The fight against advanced metastatic breast cancer has taken a significant leap forward as BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), an innovative clinical-stage biotechnology company specializing in novel immunotherapies, commences patient enrollment in a pioneering Phase 1/2 clinical study. Th...
|
|
 Contract
May 30, 2024
Sharps Technology, a leading player in the medical technology industry, is making significant strides in expanding its manufacturing capacity and global reach. In a recent development, the company signed a 5-year, $200 million syringe sales agreement, and also acquired assets to establish itself as a key player in t...
 Clinical Study
May 30, 2024
Telomir Pharmaceuticals, a leading biopharmaceutical company, is thrilled to announce two significant milestones in the development of their flagship product candidate, Telomir-1. The company has commenced a groundbreaking study to evaluate the safety of Telomir-1 when administered orally to geriatric laboratory bea...
|
|
Our most Popular Articles
|
Clinical Study
August 21, 2024
In a promising development for oncology, Bio-Path Holdings, Inc. has reported vital findings from its ongoing Phase 1/1b clinical trial of BP1001-A, a significant candidate for the treatment of advanced solid tumors. With the first patient receiving a second, higher dose of the trial drug, initial outcomes have reve...
|
Partnership
April 4, 2024
In a notable move to elevate cancer care delivery in Central Georgia, Central Georgia Cancer Care has announced a strategic partnership with the American Oncology Network (AON). As one of the nation s fastest-growing networks, AON offers community-based oncology practices resources and in-depth expertise that will h...
|
Clinical Study
September 3, 2024
In an era where vaccine development is more vital than ever, Vaxcyte, Inc. a leader in clinical-stage vaccine innovation, is poised to redefine the landscape of pneumococcal disease prevention with its 31-valent pneumococcal conjugate vaccine (PCV), VAX-31. Targeting an at-risk demographic adults aged 50 and olde...
|
|
|
Company News
|
Clinical Study
May 30, 2024
In a groundbreaking discovery, researchers have utilized the innovative Olink Explore platform to identify specific proteins circulating in the blood that may serve as early warning signs for various types of cancers up to 7 years before conventional diagnosis methods. This landmark study sheds new light on the pote...
|
Announcement
May 30, 2024
The fight against advanced metastatic breast cancer has taken a significant leap forward as BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), an innovative clinical-stage biotechnology company specializing in novel immunotherapies, commences patient enrollment in a pioneering Phase 1/2 clinical study. Th...
|
Management Announcement
May 30, 2024
Lightbridge Corporation (Nasdaq: LTBR), a pioneer in advanced nuclear fuel technology, has recently announced that its Chairman and CEO, Seth Grae, attended the White House Summit on Domestic Nuclear Deployment. The Summit, hosted by the Biden-Harris Administration on May 29, 2024, aimed to explore new ini...
|
|
|
Company News
 Management Announcement
May 30, 2024
|
Company News
Product Service News
May 30, 2024
|
Company News
 Product Service News
May 30, 2024
|
More Company News
|
Product Service News
May 30, 2024
|
Product Service News
May 30, 2024
|
Contract
May 30, 2024
|
Clinical Study
May 30, 2024
|
Announcement
May 30, 2024
|
Personnel Announcements
May 30, 2024
|
Clinical Study
May 30, 2024
|
Contract
May 30, 2024
|
Business Update
May 30, 2024
|
Business Update
May 30, 2024
|
|
|
|
Related News
|
Business Update
|
Clinical Study
|
|
Stocks
|
Personnel Announcements
|
Product Service News
|
|
Product Service News
|
|
|
|
Business News
|
|
Contract
Sharps Technology, a leading player in the medical technology industry, is making significant strides in expanding its manufacturing capacity and global reach. In a recent development, the company signed a 5-year, $200 million syringe sales agreement, and also acquired assets to establish itself as a key player in t...
|
|
Clinical Study
Telomir Pharmaceuticals, a leading biopharmaceutical company, is thrilled to announce two significant milestones in the development of their flagship product candidate, Telomir-1. The company has commenced a groundbreaking study to evaluate the safety of Telomir-1 when administered orally to geriatric laboratory bea...
|
 Financing Agreement
On May 30, 2024, Day One Biopharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing targeted therapies, made a significant announcement. The company successfully sold its Priority Review Voucher (PRV) for a staggering $108 million to an undisclosed buyer. This excitin...
|
 Product Service News
HCI Group Completes its 2024-2025 Catastrophe Reinsurance ProgramsTAMPA, Fla., May 30, 2024 - HCI Group, Inc. (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, announced today that it has completed its catastrophe reinsurance progra...
|
 Product Service News
Red Violet Inc. Outshines Competitors Amidst Strategic Partnerships and Revenue Growth In an era defined by data-driven decisions and technological advancements, companies that are able to leverage strategic partnerships and revenue growth often find themselves on a path to success. This has certainly been the case ...
|
Our Most Popular Articles
|
 Clinical Study
In a promising development for oncology, Bio-Path Holdings, Inc. has reported vital findings from its ongoing Phase 1/1b clinical trial of BP1001-A, a significant candidate for the treatment of advanced solid tumors. With the first patient receiving a second, higher dose of the trial drug, initial outcomes have reve...
|
 Partnership
In a notable move to elevate cancer care delivery in Central Georgia, Central Georgia Cancer Care has announced a strategic partnership with the American Oncology Network (AON). As one of the nation s fastest-growing networks, AON offers community-based oncology practices resources and in-depth expertise that will h...
|
 Clinical Study
In an era where vaccine development is more vital than ever, Vaxcyte, Inc. a leader in clinical-stage vaccine innovation, is poised to redefine the landscape of pneumococcal disease prevention with its 31-valent pneumococcal conjugate vaccine (PCV), VAX-31. Targeting an at-risk demographic adults aged 50 and olde...
|
More News
|
 Clinical Study
In a groundbreaking discovery, researchers have utilized the innovative Olink Explore platform to identify specific proteins circulating in the blood that may serve as early warning signs for various types of cancers up to 7 years before conventional diagnosis methods. This landmark study sheds new light on the pote...
|
|
Announcement
The fight against advanced metastatic breast cancer has taken a significant leap forward as BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), an innovative clinical-stage biotechnology company specializing in novel immunotherapies, commences patient enrollment in a pioneering Phase 1/2 clinical study. Th...
|
 Management Announcement
Lightbridge Corporation (Nasdaq: LTBR), a pioneer in advanced nuclear fuel technology, has recently announced that its Chairman and CEO, Seth Grae, attended the White House Summit on Domestic Nuclear Deployment. The Summit, hosted by the Biden-Harris Administration on May 29, 2024, aimed to explore new ini...
|
 Management Announcement
Article for:
Enphase Energy Expands Deployments of NEM 3.0 Product Solution with Installers in California
Enphase Energy, a global energy technology company and the world s leading supplier of microinverter-based solar and battery systems, has recently announced expanded deployments of its NEM 3.0 product so...
|
 Product Service News
SAN DIEGO, May 30, 2024Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company leveraging its proprietary Cloudbreak® platform to develop innovative drug-Fc conjugate (DFC) immunotherapies, is poised to make a significant contribution at the American Society for Microbiology (ASM) Microbe 2024 conference...
|
 Product Service News
Fiverr, the renowned online marketplace for freelance services, has recently made significant announcements that are set to impact both its brand and customers. With the appointment of interior design expert and CEO Bobby Berk as their brand ambassador, offering limited edition consultations and exclusive content, F...
|
 Product Service News
Microchip Increases its Wireless Portfolio with 12 New Products, Expanding Bluetooth Integration OpportunitiesMicrochip, a leading provider of semiconductor solutions, has recently unveiled 12 new products that will strengthen its wireless portfolio and provide enhanced Bluetooth integration options for designers of...
|
 Product Service News
NXP, eleQtron, and ParityQC Unveil First German-Made Quantum Computing Demonstrator for DLR Quantum Computing InitiativeIn a groundbreaking collaboration, NXP Semiconductors N.V., eleQtron, and ParityQC, working together under the QSea consortium of the DLR Quantum Computing Initiative (DLR QCI), have unveiled the f...
|
 Contract
NV5 Global, Inc., a leading provider of technology, conformity assessment, and consulting solutions, continues to solidify its position as a key player in the utility and technology sectors. The company recently announced two significant developments that further strengthen its capabilities in geospatial asset manag...
|
 Clinical Study
4D Molecular Therapeutics (4DMT), a renowned genetic medicines company, has recently shared exciting news about the interim data from its Phase 1/2 AEROW clinical trial for aerosolized 4D-710, a potential breakthrough treatment for cystic fibrosis (CF) lung disease. The company announced that the data will be presen...
|
 Announcement
Rochester, NEW YORK - April 15, 2024 - Syntec Optics Holdings, Inc. (Nasdaq: OPTX), a trailblazer in the optics industry, is making significant strides on multiple fronts, from securing groundbreaking orders to revamping its leadership team. These developments underscore Syntec Optics’ unwavering commitment to inn...
|
 Personnel Announcements
: May 30, 2024
BorgWarner Inc., a global leader in clean and efficient propulsion solutions, recently made a significant organizational announcement. The company has appointed Joseph Fadool, the current Vice President of BorgWarner Inc. and President and GM of Emissions, Thermal, and Turbo Systems, as ...
|
 Clinical Study
In an exciting move towards combating the tick-borne disease babesiosis, 60 Degrees Pharmaceuticals (60P) will commence the first-ever clinical trial of tafenoquine at Tufts Medical Center. With enrollment set to begin on June 13, 2024, this groundbreaking study aims to evaluate the effectiveness and safety of tafenoquine in treating patients suffering from this debilitating condition. Additionally, 60P has received commendable feedback from the U.S. Food and Drug Administration (FDA) regarding the tafenoquine-babesiosis clinical trial protocol, indicating no material changes are required. Moreover, the company has also ventured into researching the efficacy of tafenoquine in treating canine babesiosis, a tick-borne infection affecting our four-legged companions.1. Enrolling Patients in Trail at Tufts Medical Center:The initiation of the clinical trial at Tufts Medical Center signifies a significant milestone towards addressing the urgent need for an effective treatment for babesiosis. Tufts Medical Center, renowned for its expertise in infectious diseases, will play a crucial role in conducting this groundbreaking study. With enrollment beginning on June 13, the trial will provide a platform to evaluate the potential of tafenoquine in combating this serious tick-borne illness. The study will involve a comprehensive analysis of efficacy, safety, and tolerability, ultimately aiming to improve the quality of life for those affected by babesiosis.
|
 Contract
Embracing Sustainable Growth: Jacobs to Lead Expansion of Hamilton s Wastewater Treatment Plant In a notable advancement for urban sustainability and economic growth, Jacobs (NYSE: J), a heavyweight in engineering solutions, was recently awarded a significant contract by the City of Hamilton, Ontario. The contract e...
|
 Business Update
Li-Cycle and Daimler Truck North America Forge Partnership for Sustainable Lithium-ion Battery Recycling Amid Corporate Milestones TORONTO Li-Cycle Holdings Corp. (NYSE: LICY) (Li-Cycle or the Company), a pioneering global lithium-ion battery resource recovery enterprise, is making significant strides in supportin...
|
 Business Update
Cemex US and Clean Energy Fuels Partner to Propel Green Transportation in Southern California Cemex USA, a titan in the building materials industry, has forged a pioneering partnership with Clean Energy Fuels Corp. (NASDAQ: CLNE), the largest purveyor of ultra-clean fuel solutions for the transportation sector. This...
|
|
|
|
|
